Gilead Sciences (NASDAQ:GILD) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Gilead Sciences (NASDAQ:GILD - Free Report) in a research note issued to investors on Tuesday, MarketBeat.com reports. The firm issued an overweight rating and a $125.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald also issued estimates for Gilead Sciences' FY2025 earnings at $7.93 EPS.

Several other brokerages also recently weighed in on GILD. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their target price for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. The Goldman Sachs Group upped their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Bank of America raised their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Nine investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $108.42.

Gilead Sciences Price Performance

Shares of GILD stock traded down $2.98 during trading hours on Tuesday, hitting $103.17. The company's stock had a trading volume of 14,207,970 shares, compared to its average volume of 7,556,747. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The business has a fifty day moving average of $109.26 and a 200-day moving average of $98.03. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $119.96. The stock has a market cap of $128.46 billion, a price-to-earnings ratio of 278.84, a P/E/G ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the firm earned ($1.32) EPS. As a group, equities research analysts anticipate that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 3.06%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the completion of the transaction, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at $17,597,559.49. This represents a 1.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 302,785 shares of company stock valued at $30,540,875 over the last 90 days. 0.27% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Mather Group LLC. grew its stake in Gilead Sciences by 98.2% during the 1st quarter. Mather Group LLC. now owns 13,588 shares of the biopharmaceutical company's stock valued at $1,523,000 after purchasing an additional 6,731 shares in the last quarter. Alta Advisers Ltd grew its position in shares of Gilead Sciences by 57.3% during the first quarter. Alta Advisers Ltd now owns 6,592 shares of the biopharmaceutical company's stock worth $739,000 after buying an additional 2,400 shares in the last quarter. Lodestar Private Asset Management LLC increased its stake in shares of Gilead Sciences by 3.6% in the first quarter. Lodestar Private Asset Management LLC now owns 2,840 shares of the biopharmaceutical company's stock worth $318,000 after buying an additional 100 shares during the last quarter. Deseret Mutual Benefit Administrators raised its holdings in Gilead Sciences by 4.6% in the first quarter. Deseret Mutual Benefit Administrators now owns 17,848 shares of the biopharmaceutical company's stock valued at $2,000,000 after acquiring an additional 784 shares in the last quarter. Finally, Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences during the 1st quarter valued at $25,000. Institutional investors and hedge funds own 83.67% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.